A clue to the therapy of neurofibromatosis type 2: NF2/merlin is a PAK1 inhibitor
about
A tight junction-associated Merlin-angiomotin complex mediates Merlin's regulation of mitogenic signaling and tumor suppressive functionsIdentification and characterization of putative tumor suppressor NGB, a GTP-binding protein that interacts with the neurofibromatosis 2 proteinNeurofibromatosis type 2 protein, NF2: an uncoventional cell cycle regulator.FRAX597, a Small Molecule Inhibitor of the p21-activated Kinases, Inhibits Tumorigenesis of Neurofibromatosis Type 2 (NF2)-associated SchwannomasPAK1 is a breast cancer oncogene that coordinately activates MAPK and MET signaling3D structure analysis of PAKs: A clue to the rational design for affinity reagents and blockers.Growth inhibitory and anti-tumour activities of OSU-03012, a novel PDK-1 inhibitor, on vestibular schwannoma and malignant schwannoma cells.The ErbB inhibitors trastuzumab and erlotinib inhibit growth of vestibular schwannoma xenografts in nude mice: a preliminary studyPAK kinase regulates Rac GTPase and is a potential target in human schwannomasSchwannomin/merlin promotes Schwann cell elongation and influences myelin segment length.Anti-cancer effect of novel PAK1 inhibitor via induction of PUMA-mediated cell death and p21-mediated cell cycle arrest.The NF2 tumor suppressor gene product, merlin, inhibits cell proliferation and cell cycle progression by repressing cyclin D1 expressionPAK1 as a therapeutic target.Merlin: a tumour suppressor with functions at the cell cortex and in the nucleus.Contact-dependent inhibition of EGFR signaling by Nf2/MerlinPak protein kinases and their role in cancer.Neurofibromatosis 2 (NF2) tumor suppressor merlin inhibits phosphatidylinositol 3-kinase through binding to PIKE-LDevelopment of small-molecule inhibitors of the group I p21-activated kinases, emerging therapeutic targets in cancer.Merlin: the wizard requires protein stability to function as a tumor suppressor.Untangling the complexity of PAK1 dynamics: The future challenge.PAK signaling in cancer.Quantitative Proteomics Reveals Fundamental Regulatory Differences in Oncogenic HRAS and Isocitrate Dehydrogenase (IDH1) Driven Astrocytoma.Validation of the p21-activated kinases as targets for inhibition in neurofibromatosis type 2.HEI10 negatively regulates cell invasion by inhibiting cyclin B/Cdk1 and other promotility proteins.Schwann cell development, maturation and regeneration: a focus on classic and emerging intracellular signaling pathwaysNF2 binds PAK1
P2860
Q24299493-6601BA1B-8247-47F3-AAC9-5D7BF760022CQ24338893-4EDE451A-FD61-4117-993E-EEB9AAA3DB24Q26825296-AF90497B-0780-46F2-AE03-EC6817697413Q27679769-7A3A1BBA-10BC-43F6-A85A-4CA79BF57162Q28253621-657CD698-4A3A-44DA-B86B-D2376A000457Q30009979-2BEFD1E5-2992-470A-A208-0E45F17637D2Q30481231-8828CC8C-ACE2-4F96-833F-224CEFF6AEC8Q30487287-AC78699A-807A-481C-997B-7AC4CDEC9DF3Q30490902-16C5E426-9609-45E4-97D9-FDC708E49AA2Q30502106-7B3BB599-5ED1-4CD7-B192-95FF68E4F184Q33618830-4CB573C5-F3A8-468E-BC18-4BD2E5A353C1Q33707642-85CEF207-AA41-4A0E-9DC4-42BDFABAB059Q35108164-EBF576B4-3C44-4E18-A6CD-26D028CAC3B4Q35880377-4292CF37-C6D9-404E-8D97-32368F328C13Q36118464-41790589-BFA9-467B-B648-F9F5CE335809Q37376062-9ADAAFB0-F6BF-4AB4-B0B7-CC461325427AQ37709703-E296CE6A-EA92-4948-9B77-0C670BD1F2F5Q37715015-35F6F247-E8A4-4499-AC21-DFBD24220755Q38023101-4C891D4E-512D-4CC0-A3C6-C106C6AB3F22Q38057750-03104BEB-1D02-44C0-8EAA-9F4C11E91666Q38060732-F675C0DE-C9CD-4DFD-8FE6-66D2346D7842Q38731795-4AB9560D-EA9C-47B7-9A10-A4EB665EFDFEQ40040209-35CED98C-A9CC-4D92-A266-53CB40716E85Q40171646-24CDE630-6512-4EC4-A5E2-72E717F489A8Q41429732-255ED3C7-45E2-4751-AAE2-014DE53C909CQ50299164-C39FA20D-04C4-498C-A711-F26D7A5080AA
P2860
A clue to the therapy of neurofibromatosis type 2: NF2/merlin is a PAK1 inhibitor
description
2004 թուականի Յունուարին հրատարակուած գիտական յօդուած
@hyw
2004 թվականի հունվարին հրատարակված գիտական հոդված
@hy
artículu científicu espublizáu en 2004
@ast
im Januar 2004 veröffentlichter wissenschaftlicher Artikel
@de
scientific journal article
@en
vedecký článok (publikovaný 2004/01/01)
@sk
vědecký článek publikovaný v roce 2004
@cs
wetenschappelijk artikel (gepubliceerd op 2004/01/01)
@nl
наукова стаття, опублікована в січні 2004
@uk
مقالة علمية (نشرت عام 2004)
@ar
name
A clue to the therapy of neurofibromatosis type 2: NF2/merlin is a PAK1 inhibitor
@ast
A clue to the therapy of neurofibromatosis type 2: NF2/merlin is a PAK1 inhibitor
@en
A clue to the therapy of neurofibromatosis type 2: NF2/merlin is a PAK1 inhibitor
@nl
type
label
A clue to the therapy of neurofibromatosis type 2: NF2/merlin is a PAK1 inhibitor
@ast
A clue to the therapy of neurofibromatosis type 2: NF2/merlin is a PAK1 inhibitor
@en
A clue to the therapy of neurofibromatosis type 2: NF2/merlin is a PAK1 inhibitor
@nl
prefLabel
A clue to the therapy of neurofibromatosis type 2: NF2/merlin is a PAK1 inhibitor
@ast
A clue to the therapy of neurofibromatosis type 2: NF2/merlin is a PAK1 inhibitor
@en
A clue to the therapy of neurofibromatosis type 2: NF2/merlin is a PAK1 inhibitor
@nl
P2093
P1433
P1476
A clue to the therapy of neurofibromatosis type 2: NF2/merlin is a PAK1 inhibitor
@en
P2093
Anjali Tikoo
C. Oliver Hanemann
Guang-Hui Xiao
Hiroshi Maruta
John Huynh
Joseph R. Testa
Marco Giovannini
Tamara Utermark
Yumiko Hirokawa
P577
2004-01-01T00:00:00Z